
- /
- Supported exchanges
- / US
- / TSHA.NASDAQ
Taysha Gene Therapies Inc (TSHA NASDAQ) stock market data APIs
Taysha Gene Therapies Inc Financial Data Overview
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Taysha Gene Therapies Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Taysha Gene Therapies Inc data using free add-ons & libraries
Get Taysha Gene Therapies Inc Fundamental Data
Taysha Gene Therapies Inc Fundamental data includes:
- Net Revenue: 8 098 K
- EBITDA: -88 008 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Taysha Gene Therapies Inc News

Taysha Gene Therapies regains full rights to TSHA-102
designer491/iStock via Getty Images * Taysha Gene Therapies (NASDAQ:TSHA [https://seekingalpha.com/symbol/TSHA]) has announced that it has regained complete rights to its leading program, TSHA-102,...


I-Mab morphs into ‘hub-and-spoke’ biotech; Astellas passes on Taysha gene therapy
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving I-Mab Biopha...

Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?
PersonalisPSNL shares ended the last trading session 20.5% higher at $10.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compa...

Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?
Personalis PSNL shares ended the last trading session 20.5% higher at $10.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This comp...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.